STALICLA SA

STALICLA is a Swiss clinical stage biopharmaceutical company applying precision medicine drug development for patients with neurodevelopmental disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD). STALICLA is on a unique mission to identify patient subgroups and develop tailored treatments. Its DEPI technology is the first platform specifically developed to enable precision medicine in complex NDDs. STALICLA currently has one candidate in the clinic and plans to bring two assets into Phase 2 in 2022. The company is also advancing collaborative alliances with strategic third party pipelines.